CN106620690A - Stable antibody preparation - Google Patents
Stable antibody preparation Download PDFInfo
- Publication number
- CN106620690A CN106620690A CN201510726430.6A CN201510726430A CN106620690A CN 106620690 A CN106620690 A CN 106620690A CN 201510726430 A CN201510726430 A CN 201510726430A CN 106620690 A CN106620690 A CN 106620690A
- Authority
- CN
- China
- Prior art keywords
- preparation
- egfr
- antibody
- concentration
- cyclodextrin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
The present invention relates to the technical field of biology, discloses a stable antibody preparation, specifically a high-concentration anti-EGFR antibody preparation containing hyaluronidase and cyclodextrin, wherein the preparation has good stability, is particularly suitable for subcutaneous injection, and can be used for treating human head and neck squamous cell carcinoma, colorectal cancer, pancreatic cancer, non-small cell lung cancer, bladder cancer, and other diseases.
Description
Technical field
The present invention relates to biomedicine technical field, more specifically, a kind of the invention discloses stable preparation.
Background technology
EGF-R ELISA (EGFR) is the weight of a kind of epidermal growth factor cell propagation and signal transduction
Acceptor is wanted, EGFR in combination with its part by producing effect.The ligands specific of EGFR is EGF and EGF
Related polypeptide, including transforming growth factor α (TGF- α), amphiregulin and Heparin-binding EGF samples growth because
Son.In order to activate EGFR, ligands, EGF (monomer) in combination with and connect two adjacent receptor chains, make
The intracellular kinase local of acceptor mutual phosphorylation on multiple tyrosine, tyrosine kinase activity is improved so as to can
To activate several signal path such as ras-MAPK paths, PI3 kinase pathway and JAK/STAT paths etc..EGFR
Structure activates excessively EGFR caused by (not needing part) and autocrine stimulation after acceptor overexpression or mutation
Function is related to kinds cancer generation.The tumorigenesis effect of EGFR include DNA synthesis start, promote cell growth,
Invasion and attack and transfer, specific knockdown EGFR can cause cell cycle capture, Apoptosis and cancer cell
Differentiation.Research finds, cancer that EGFR originates in various people's epithelial tissues (as bladder, mammary gland, uterine neck,
Colon, neck, kidney, lung, pancreas and prostate etc.) in have the expression of varying level, EGFR is in knot
Intestines carcinoma of the rectum expression rate is up to 25-77%, and related to the deterioration of tumour and poor prognosis.Just because of EGFR
With These characteristics, the antibody drug with EGFR as target spot is continuously developed, and some products have been used for tumour
The clinical practice for the treatment of：
(Erbitux, cetuximab, Cetuximab) is a kind of mouse of Imclone companies exploitation
The monoclonal anti EGFR antibody that/people is fitted together to.It is a kind of aseptic, clear and bright, colourless liquid, pH 7.0
To 7.4, wherein easy visible, white, amorphous Cetuximab particulate in a small amount may be contained.Per bottle Erbitux
Comprising：The sodium chloride of cetuximab, 8.48mg/mL of 2mg/mL, the phosphoric acid hydrogen two of 1.88mg/mL
The water of sodium seven, 0.41mg/mL biphosphate sodium-hydrates, and water for injection (USP).Cetuximab can
With with EGFR acceptors to be higher by the affinity of about 5 to 10 times of endogenous ligands and EGFR specific bonds, so as to competing
The combination of striving property agonist ligand and EGFR, the combination for blocking acceptor and part suppresses ligand-mediated EGFR then
The activation of EGFR-TK, so that various by EGFR in tumour cell or the stroma cell in tumor microenvironment
The cell processes that signal path is adjusted are blocked, including EGFR is lowered, the suppression of Intracellular signals, cell week
The suppression of phase, the induction of apoptosis, the suppression that DNA is repaired, the suppression of Angiogenesiss, Tumor Cell Migration,
It is aggressive and it is metastatic suppress etc..U.S. FDA was ratified in 2 months 2004It is straight for tying
The treatment of intestinal cancer, FDA in 2006 also ratifies it to be used to treat head and neck neoplasm.
(Victibix, panitumumab) is that the one kind developed by Amgen companies is used to control
The full human monoclonal antibodies of anti-EGFR of metastatic colorectal carcinoma after chemotherapy failure are treated,It is a kind of
Aseptic, colourless, pH 5.6 to 6.0 liquid preparation, there is tri- kinds of specifications of 5mL, 10mL, 20mL, wherein
The single of 5mL specifications contains sodium chloride, the 34mg vinegar of panitumumab, 29mg of 100mg with bottle
Sour sodium, and water for injection, USP；The single of 10mL specifications panitumumab of the bottle containing 200mg,
The sodium chloride of 58mg, the sodium acetate of 68mg, and water for injection, USP；The single of 20mL specifications is with little
Bottle Victibix containing 400mg, 117mg sodium chloride, 136mg sodium acetates and water for injection, USP.
2006It is approved by the fda in the United States for treatment transfer colon cancer.
201010148069.0 disclose a kind of monoclonal antibody against EGFR with high-affinity with it in system
Purposes in standby antineoplastic；Wherein the amino acid sequence of weight chain variable district (VH) is SEQ IDNO：14,
The amino acid sequence of light chain variable district (VL) is SEQ ID NO：6 or SEQ ID NO：12 antibody with
The affinity of EGFR compares at least 10 times of raising with Cetuximab.
……
But, the preparation of existing these anti-egfr antibodies is the preparation of low concentration, and it is not suitable for
Hypodermic injection, because the volume ratio intravenous infusion volume for hypodermic drug solution is much smaller, institute
Require that antibody preparation concentration is typically up to the level of tens, even hundreds of mg/ml with it.And hypodermic injection is given
Medicine using more convenient, safe and reliable, and is favorably improved patient's compared with intravenous injection administration
Quality of life, the consultation time for reducing patient, have become at present following developing direction.But, high concentration
Antibody-solutions it is more unstable for the preparation of low concentration, easily there is protein aggregation, and assemble easy
The bioavailability for causing active antibodies is reduced, pharmacokinetics changes, unfavorable immunogenicity etc. is asked
Topic generation (Frokjaer, S. and Otzen, D. Ε., Nat.Rev.Drug.Discov.4:298_306
(2005)；Jiskoot, W. and Crommelin, D.J.A., EJHP Practice 12：20-21(2006)).
It is by adding excipient to protein solution, the stabilizer bag for often using to prevent from present assembling common strategy one
Include sugar, salt, free amino acid, polyalcohol, polyethylene glycol (PEG) and protein-protein phase can be reduced
The other polymers of interaction, such as polysorbate (polysorbates) or poloxamer (Nema, S.^A,
PDAJournal of Pharmaceutical Science and Technology 51:166-171(1997))；Or it is logical
Cross and add appropriate excipient (including freeze drying protectant) lyophilized to prevent protein aggregation.But,
When these strategies are applied to the high concentration ejection preparation of more than mg/ml up to a hundred, effect is less desirable.
Therefore, how to develop a kind of stable antibody preparation of the high concentration for being suitable to hypodermic injection is still very
It is necessary.
The content of the invention
Applicant of the present invention develops a kind of stable antibody system of high concentration through substantial amounts of research experiment
Agent, said preparation includes hyaluronidase and cyclodextrin；Said preparation formula is particularly suitable for preparing the highly concentrated of injection
Degree anti-egfr antibodies preparation.Specifically, the invention discloses：
1st, a kind of stable high concentration antibody preparation, it is included：Antibody, hyaluronidase and cyclodextrin.
2nd, the preparation described in above-mentioned 1, it also includes one or more stabilizer, nonionic surface active agent or slow
Electuary.
3rd, a kind of stable high concentration antibody preparation, it is included：
A. antibody more than concentration 50mg/ml；
B.1 to 150mM buffers；
C.15 it is sugared to 250mM；
D.0.01 to 0.1% nonionic surface active agent；
E.40000 the hyaluronidase of individual more than U/ml；With
F.20% to 50% cyclodextrin.
4th, the arbitrary preparations of above-mentioned 1-3, it is characterised in that the hyaluronidase is rHuPH20.
5th, the arbitrary preparations of above-mentioned 1-4, the cyclodextrin is HP- beta cyclodextrins.
6th, the arbitrary preparations of above-mentioned 1-4, the sugar is 80 to 150mM sucrose.
7th, the arbitrary preparations of above-mentioned 1-6, the nonionic surface active agent is selected from the group：Polysorbate 20,
Polyoxyethylene sorbitan monoleate and polyethylene-polypropylene copolymer.
8th, the nonionic surface active agent described in above-mentioned 7 is 0.02% to 0.08% polyoxyethylene sorbitan monoleate for concentration.
9th, the arbitrary preparations of above-mentioned 1-5, the antibody is the anti-egfr antibodies of concentration 100 to 250mg/ml.
10th, a kind of stable high concentration antibody preparation, it is included：
A. concentration 100 arrives the anti-egfr antibodies of 300mg/ml；
B.50 to the histidine buffer of 150mM；
C.100 to 150mM sucrose；
D.0.02% to 0.08% polyoxyethylene sorbitan monoleate；
E.40000 the rHuPH20 of individual U/ml to 70000 U/ml；With
F.15% to 40% HP- beta cyclodextrins.
Test result indicate that, the preparation of the present invention can effectively prevent high concentration antibody from sending out in prolonged storage
Raw aggregation, so as to provide a kind of antibody preparation with good stability, even if said preparation is at normal temperatures
With preferable stability, it is ensured that the preparation rational shelf-life.
The anti-egfr antibodies preparation of the present invention, it is straight that it can be used for the incidence squamous cell carcinoma for the treatment of people, colon
Intestinal cancer, cancer of pancreas, non-small cell lung cancer, carcinoma of urinary bladder etc..Preferably can be used as injection aqueous solution formulation
Use, more preferably solution can be filled and be used by hypodermic injection in precharging type syringe.
Specific embodiment
The following examples are in order to demonstrate the invention and help those skilled in the art to carry out and use this
Invention, should not be understood as limitation of the present invention.
In following examples, anti-egfr antibodies are (with reference to the side disclosed in China Patent No. 201010148069.0
Method is prepared), other experiment materials are obtained by commercial channel, such as HP- beta cyclodextrins (purchase
It is biological from source leaf), rHuPH20 (Halozyme), histidine (river Lay is biological), sucrose (promise occasion are biological),
Polyoxyethylene sorbitan monoleate (containing the permanent wound in day) etc..
Any one of ordinary skill in the art will be understood that will be included in the composition various groups
Point combination can complete in any suitable order, i.e. can add first, middle addition or
Finally add buffer, and also adding first, in middle addition or in last addition surfactant
Deng.Equally, one of ordinary skill in the art will be understood that these chemical substances in some combinations
In some be incompatible, and therefore, they can easily by with similar quality but relevant mixed
It is that compatible different chemical substance replaces in compound.
In addition to especially indicating, the content % ratio in preparation is quality concentration of volume percent (w/v), solution PH
Can adjust as needed, preferred 4-8.
The hyaluronidase of embodiment 1 and cyclodextrin resist the impact of body preparation
25 DEG C of stability studies containing hyaluronidase and the anti-egfr antibodies preparation of cyclodextrin.The preparation is removed
Can also contain outside hyaluronidase and cyclodextrin other according to the excipient gone out given in table 1.
Table 1：Anti-egfr antibodies pharmaceutical formulation
Above-mentioned sample formulation is incubated 60 days at 35 DEG C, then passes through in the 0th, 20,40,60 days time points respectively
SDS-PAGE is analyzed.SDS-PAGE is used as a kind of analytical technology, can be according to molecular weight from natural egg
Free and HMW species is isolated in white matter.Due in the antibody preparation of high concentration, macromolecular
Antibody has high aggregation tendency, and non-reduced SDS-PAGE is used to evaluate covalent aggregation.
Table 2：Different formulations anti-egfr antibodies preparation aggregation SDS-PAGE analysis results
SDS-PAGE analysis results show that F1, F2 preparation for not adding hyaluronidase and cyclodextrin is more also easy to produce
Antibody aggregates, added with preparation F5, F6, F7, F8 of two kinds of auxiliary materials of hyaluronidase and cyclodextrin aggregation is not almost produced,
With more preferable stability.
The impact of the sugar antagonism body preparation of embodiment 2
Evaluate the impact of the sugar antagonism EGFR antibody preparation stability of varying level.We are positioned in sample
- 20 DEG C, 8 DEG C and 45 DEG C, under conditions of 60% humidity and in different time points SE-HPLC methods are passed through
The aggregation situation of antibody in detection anti-egfr antibodies preparation.
Table 3:Anti-egfr antibodies pharmaceutical formulation table
| Sequence number | Composition | F9 | F10 | F11 | F12 |
| 1 | Anti-egfr antibodies (mg/ml) | 200 | 200 | 200 | 200 |
| 2 | Sucrose (mM) | 20 | 100 | 200 | 400 |
| 3 | Histidine buffer (mM) | 150 | 150 | 150 | 150 |
| 4 | Polyoxyethylene sorbitan monoleate (%) | 0.02 | 0.02 | 0.02 | 0.02 |
| 5 | RHuPH20 (individual U/ml) | 50000 | 50000 | 50000 | 50000 |
| 6 | HP- beta cyclodextrins (%) | 35 | 35 | 35 | 35 |
Table 4:The impact of sugar antagonism EGFR antibody preparation stability
As shown in Table 4 experimental result understands that sugar antagonism EGFR antibody preparation stability has certain impact, excellent
Selection of land, when sucrose is 100-200mM, preparation stability is preferable.
The surfactant of embodiment 3 resists the impact of body preparation
From nonionic surfactant polysorbate (such as polysorbate 20 or 80) and Pa Luoshamu is (for example
Pa Luoshamu 188 or 168) in filter out the optimal candidate in terms of stability.We are mainly by right
Than analyzing the polysorbate 20 of different content and the anti-egfr antibodies preparation of Pa Luoshamu 188 in storage process
In aggregation situation, so as to analyze impact of the different surfaces activating agent to preparation stability.We put in sample
It is placed in 30 DEG C, anti-EGFR is detected by SE-HPLC methods under conditions of 60% humidity and in different time points
The aggregation situation of antibody in antibody preparation.
Table 5:Anti-egfr antibodies pharmaceutical formulation table
Table 6：:Surfactant resists the impact of EGFR antibody preparation stability
From upper table 6, compared with the preparation containing the surfactants of Pa Luoshamu 188, polyoxyethylene sorbitan monoleate
With less aggregation, it is preferable that the tool of the anti-egfr antibodies preparation containing 0.06% polyoxyethylene sorbitan monoleate
There is more preferable stability.
The preparation and stability test of the anti-egfr antibodies preparation of embodiment 4
The anti-egfr antibodies preparation optimization formula of table 7
| Anti-egfr antibodies | 200mg/ml |
| Sucrose | 120mM |
| Histidine buffer | 100mM |
| Polyoxyethylene sorbitan monoleate | 0.06% |
| rHuPH20 | 55000 U/ml |
| HP- beta cyclodextrins | 35% |
| PH | 5.5-8 |
The pharmaceutical solutions compound method with reference to described in the ZL200610147281.9 prepare table 7 described in fill a prescription it is anti-
EGFR antibody-solutions preparations.Then anti-egfr antibodies pharmaceutical solutions is stored at -20 DEG C, 5 DEG C and 25 DEG C to exist
Storage starts, 1 month, 3 months and 6 months aggregation situations afterwards, anti-by SE-HPLC analyses
The stability of EGFR antibody-solutions preparations.The results are shown in Table 8.
Table 8：Anti-egfr antibodies pharmaceutical solutions stability test result
(remarks：3 groups of parallel preparations of each temperature measuring are averaged)
In addition, we also by described in the table 9 for preparing fill a prescription anti-egfr antibodies pharmaceutical solutions in air layer
Flow down with 0.2 μm of filter sterilised and store at 60 DEG C.Said preparation is analyzed in storage by SE-HPLC
Deposit beginning, 10 days, 20 days, 30 days stability afterwards.The results are shown in Table 9.
Table 9:Anti-egfr antibodies pharmaceutical solutions stability test result
| Determinea | 0 day | 10 days | 20 days | 30 days |
| The aggregation % that SE-HPLC is determined | 0.51 | 1.20 | 1.95 | 2.75 |
(remarks：3 groups of parallel preparations of each temperature measuring are averaged)
From above-mentioned table 8-9, the anti-egfr antibodies pharmaceutical solutions stability of the present invention is preferable, even if normal
Still there is preferable stability in the case of temperature or higher temperature.
In addition, the researcher of the present invention is also anti-to other business-like cetuximab, panitumumab etc.
EGFR antibody carries out above-mentioned 1-5 experiments, and preparation stability is similar with above-mentioned experimental result, is respectively provided with preferably
Stability.
The anti-egfr antibodies preparation of the present invention, it is straight that it is used for the incidence squamous cell carcinoma for the treatment of people, colon
Intestinal cancer, cancer of pancreas, non-small cell lung cancer, carcinoma of urinary bladder etc..Made preferably as injection aqueous solution
With more preferably solution being filled and be used by hypodermic injection in precharging type syringe.
Claims (10)
1. a kind of stable high concentration antibody preparation, it is included：Antibody, hyaluronidase and cyclodextrin.
2. preparation according to claim 1, it also includes one or more stabilizer, nonionic surface active agent or buffer.
3. a kind of stable high concentration antibody preparation, it is included：
A. antibody more than concentration 50mg/ml；
B.1 to 150mM buffers；
C.15 it is sugared to 250mM；
D.0.01 to 0.1% nonionic surface active agent；
E.40000 the hyaluronidase of individual more than U/ml；With
F.20% to 50% cyclodextrin.
4. according to the arbitrary preparation of claim 1-3, it is characterised in that the hyaluronidase is rHuPH20.
5., according to the arbitrary preparation of claim 1-3, the cyclodextrin is HP- beta cyclodextrins.
6., according to the arbitrary preparation of claim 1-3, the sugar is 80 to 150mM sucrose.
7., according to the arbitrary preparation of claim 1-3, the nonionic surface active agent is selected from the group：It is polysorbate 20, poly-
Sorb ester 80 and polyethylene-polypropylene copolymer.
8. nonionic surface active agent according to claim 7 is the polyoxyethylene sorbitan monoleate of concentration 0.02% to 0.08%.
9. a kind of stable high concentration antibody preparation, it is included：
A. concentration 100 arrives the anti-egfr antibodies of 300mg/ml；
B.50 to the histidine buffer of 150mM；
C.100 to 150mM sucrose；
D.0.02% to 0.08% polyoxyethylene sorbitan monoleate；
E.40000 the rHuPH20 of individual U/ml to 70000 U/ml；With
F.15% to 40% HP- beta cyclodextrins.
10. preparation according to claim 9, it is included：
A. anti-egfr antibodies of concentration 200mg/ml；
B.100mM histidine buffer；
C.120mM sucrose；
D.0.06% polyoxyethylene sorbitan monoleate；
E.55000 the rHuPH20 of individual U/ml；With
F.35% HP- beta cyclodextrins.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510726430.6A CN106620690A (en) | 2015-10-30 | 2015-10-30 | Stable antibody preparation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510726430.6A CN106620690A (en) | 2015-10-30 | 2015-10-30 | Stable antibody preparation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106620690A true CN106620690A (en) | 2017-05-10 |
Family
ID=58809133
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510726430.6A Pending CN106620690A (en) | 2015-10-30 | 2015-10-30 | Stable antibody preparation |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106620690A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107898756A (en) * | 2017-12-22 | 2018-04-13 | 东曜药业有限公司 | It is a kind of for high concentration Buddhist nun's trastuzumab preparation for subcutaneously or intramuscularly injecting and its preparation method and application |
| US11634485B2 (en) | 2019-02-18 | 2023-04-25 | Eli Lilly And Company | Therapeutic antibody formulation |
-
2015
- 2015-10-30 CN CN201510726430.6A patent/CN106620690A/en active Pending
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107898756A (en) * | 2017-12-22 | 2018-04-13 | 东曜药业有限公司 | It is a kind of for high concentration Buddhist nun's trastuzumab preparation for subcutaneously or intramuscularly injecting and its preparation method and application |
| US11634485B2 (en) | 2019-02-18 | 2023-04-25 | Eli Lilly And Company | Therapeutic antibody formulation |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104736175B (en) | Prolactin antagonist receptor antibody preparation | |
| JP5878144B2 (en) | Subcutaneous anti-HER2 antibody preparation | |
| WO2017054646A1 (en) | Stable anti-pd-1 antibody pharmaceutical preparation and application thereof in medicine | |
| AU2002358533B2 (en) | Lyophilized preparation containing antibodies to the EGF receptor | |
| TW201414496A (en) | Antibody and protein formulations | |
| EA026226B1 (en) | ARGININE-FREE Fc-FUSION POLYPEPTIDE COMPOSITIONS AND METHODS OF USE THEREOF | |
| TW201513882A (en) | Anti-prolactin receptor antibody formulations | |
| AU2016382786A1 (en) | Buffered formulations of bevacizumab | |
| CN104922668B (en) | A kind of stable anti-VEGF antibody preparation and application thereof | |
| CN102961745B (en) | Antibody composition preparation and application thereof | |
| JP2022521624A (en) | Preparation containing anti-CD47 antibody, its preparation method and use | |
| CN104906576B (en) | For hypodermic high concentration anti-VEGF antibody preparaton | |
| JP2023085555A (en) | PHARMACEUTICAL PREPARATION OF ANTI-Her2 ANTIBODY DRUG CONJUGATE | |
| TWI787161B (en) | Pharmaceutical composition comprising anti-human tslp receptor antibody | |
| CN106620690A (en) | Stable antibody preparation | |
| CN108261544A (en) | The stable pharmaceutical preparation for including CD147 monoclonal antibodies | |
| RU2589691C2 (en) | Stable composition of antibody specifically bound with her2 receptors and preparation method thereof | |
| CN106456784A (en) | Stable protein formulations comprising a molar excess of sorbitol | |
| CN104193828A (en) | Recombinant fusion protein capable of simultaneously blocking HER2 and VEGFR signal paths | |
| CN113194925A (en) | Antibody formulations | |
| CN107249634A (en) | Pharmaceutical preparation comprising anti-egfr antibodies | |
| US20170233491A1 (en) | Dosage and administration of combination therapies comprising istiratumab, uses and methods of treatment | |
| CN107773755A (en) | The injection formulation of anti-epidermal growth factor receptor monoclonal antibody | |
| CN117159703B (en) | Pharmaceutical composition containing anti-LAG-3 antibody and application thereof | |
| EP4079294A2 (en) | Stable and highly concentrated formulation of the antibody nimotuzumab |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20170510 |
|
| WD01 | Invention patent application deemed withdrawn after publication |